ArticleFrontiers in pharmacology2026
5-methoxyresorcinol mitigates postmenopausal osteoporosis through regulation of the PI3K-AKT-GSK3β signaling pathway and ROS homeostasis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Osteoporosis is a systemic skeletal disease characterized by excessive osteoclast-mediated bone resorption. This study aimed to evaluate the therapeutic potential of 5-methoxyresorcinol (MR) in osteoporosis and to clarify its underlying mechanisms. Methods: Network pharmacology analysis was performed to identify shared targets between MR and osteoporosis. Results: Network pharmacology analysis identified 107 potential targets of MR and 8,060 osteoporosis-associated genes, of which 50 were overlapping targets. Among these targets, the PI3K-AKT signaling pathway showed significant enrichment. Conclusion: MR attenuates osteoporosis by suppressing osteoclast differentiation and function through regulating PI3K-AKT-GSK3β axis and ROS homeostasis, supporting its potential as a promisingtherapeutic candidate for osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.